The potential underlying mechanisms by which prebiotics lower the risk of hypertension include reducing lipid and cholesterol synthesis by increasing SCFA production; reducing obesity through improving satiety and lowering food intake through the gut’s production of endogenous glucagon-like peptide-1; enhancing hepatic insulin sensitivity and reducing insulin resistance by SCFAs; and improving the digestive tract’s ability to absorb nutrients [225]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.